1. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
- Author
-
Carlos Anaya, Jill K. Hacker, Ursula Schulze-Gahmen, Monica Haw, Carl L. Hanson, Chantha Kath, Debra A. Wadford, Miguel Garcia-Knight, Phillip A. Frankino, Mir M. Khalid, Jing Cheng, Claudia Sanchez San Martin, Donna Ferguson, Xianding Deng, Melanie Ott, Steve Miller, Raul Andino, Liana F. Lareau, John Bell, Mary Kate Morris, G. Renuka Kumar, Jennifer M. Hayashi, Charles Y. Chiu, Dustin R. Glasner, Peter V. Lidsky, Peera Hemarajata, Haridha Shivram, Bharath Sreekumar, Stacia K. Wyman, Sarah McMahon, Yinghong Xiao, Nicole M. Green, Scot Federman, Pei-Yi Chen, Venice Servellita, Taha Y. Taha, Nikitha P. Reddy, Jessica Streithorst, Joanna Balcerek, Candace Wang, Jordan E. Taylor, Kevin Reyes, Camille R. Simoneau, Alicia Sotomayor-Gonzalez, Amelia S. Gliwa, and Alex Espinosa
- Subjects
coronavirus ,genomic epidemiology ,Antibodies, Viral ,medicine.disease_cause ,spike protein ,Medical and Health Sciences ,Neutralization ,0302 clinical medicine ,vaccine ,Monoclonal ,antibody neutralization ,pseudovirus infectivity studies ,Viral ,Neutralizing ,Lung ,Infectivity ,0303 health sciences ,Mutation ,biology ,L452R mutation ,Transmission (medicine) ,Antibodies, Monoclonal ,Biological Sciences ,Spike Glycoprotein ,Titer ,Infectious Diseases ,Spike Glycoprotein, Coronavirus ,Pneumonia & Influenza ,Antibody ,viral whole-genome sequencing ,variant of concern ,Biotechnology ,B.1.427/B.1.429 ,N501Y mutation ,General Biochemistry, Genetics and Molecular Biology ,Antibodies ,Article ,Vaccine Related ,03 medical and health sciences ,medicine ,Humans ,Viral shedding ,molecular dating ,030304 developmental biology ,Whole Genome Sequencing ,SARS-CoV-2 ,pandemic ,Prevention ,COVID-19 ,Pneumonia ,Antibodies, Neutralizing ,Virology ,genomic surveillance ,Coronavirus ,Emerging Infectious Diseases ,Good Health and Well Being ,variant ,Cell culture ,biology.protein ,Immunization ,20C/L452R ,030217 neurology & neurosurgery ,Developmental Biology - Abstract
We identified an emerging SARS-CoV-2 variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the Western United States. Named B.1.427/B.1.429 to denote its 2 lineages, the variant emerged in May 2020 and increased from 0% to >50% of sequenced cases from September 2020 to January 2021, showing 18.6-24% increased transmissibility relative to wild-type circulating strains. The variant carries 3 mutations in the spike protein, including an L452R substitution. We found 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation common to variants B.1.1.7, B.1.351, and P.1. Antibody neutralization assays revealed 4.0 to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively. The increased prevalence of a more transmissible variant in California exhibiting decreased antibody neutralization warrants further investigation., A SARS-CoV-2 variant of concern bearing the L452R spike protein mutation is widely circulating in California, United States, and demonstrates increased transmissibility, infectivity, and avoidance of antibody neutralization.
- Published
- 2021